Concord Biotech

Price chart

Previous close

₹612.20

Open

₹620.90

Day high

₹625.20

Day low

₹593.10

Listed on NSE since 18 August 2023.

Market value

₹13,236 Cr

P/E (trailing)

47.39

EPS (trailing)

₹13.35

Price to book

6.48

Dividend yield

0.60%

Return on equity

14.3%

Debt to equity

0.00

Profit margin

24.1%

Beta

0.44

Volume today

2.60 L

Average volume

3.26 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Concord Biotech’s results filed with NSE, consolidated (the whole group). Net profit is the share of Concord Biotech’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Concord Biotech’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Industry

Biotechnology

Based in

Ahmedabad

Employees

1,624

Company website · Profile: Yahoo Finance

No headlines name Concord Biotech in the last day or two.

• Bonus 1:1

  Bonu · ex-date 4 November 2026

• Dividend - Rs 7.55 Per Share

  Dividend · ex-date 24 July 2026

• Dividend - Rs 10.70 Per Share

  Dividend · ex-date 3 September 2025

• Annual General Meeting

  Action · ex-date 21 June 2024

• Dividend - Rs 8.75 Per Share

  Dividend · ex-date 21 June 2024 · record date 22 June 2024

Source: NSE. Latest first.